The International Vaccine Institute announced the first participant received Bharat Biotech International Ltd’s (BBIL) Chikungunya vaccine candidate (BBV87) in a Phase II/III clinical trial in Costa Rica, marking the start of a multi-country study led by IVI in partnership with BBIL and funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India.
- Read more about New Chikungunya vaccine is under trial
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/new-chikungunya-vaccine-is-under-trial
No comments:
Post a Comment